FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4225319387> ?p ?o ?g. }

• W4225319387 endingPage "e384" @default.
• W4225319387 startingPage "e374" @default.
• W4225319387 abstract "Remarkable improvements in outcomes for many haematological malignancies have been driven primarily by a proliferation of novel therapeutics over the past two decades. Targeted agents, immune and cellular therapies, and combination regimens have adverse event profiles distinct from conventional finite cytotoxic chemotherapies. In 2018, a Commission comprising patient advocates, clinicians, clinical investigators, regulators, biostatisticians, and pharmacists representing a broad range of academic and clinical cancer expertise examined issues of adverse event evaluation in the context of both newer and existing therapies for haematological cancers. The Commission proposed immediate actions and long-term solutions in the current processes in adverse event assessment, patient-reported outcomes in haematological malignancies, toxicities in cellular therapies, long-term toxicity and survivorship in haematological malignancies, issues in regulatory approval from an international perspective, and toxicity reporting in haematological malignancies and the real-world setting. In this follow-up report, the Commission describes progress that has been made in these areas since the initial report." @default.
• W4225319387 created "2022-05-05" @default.
• W4225319387 creator A5000437754 @default.
• W4225319387 creator A5001898266 @default.
• W4225319387 creator A5002972322 @default.
• W4225319387 creator A5003110303 @default.
• W4225319387 creator A5004180407 @default.
• W4225319387 creator A5004674303 @default.
• W4225319387 creator A5017390274 @default.
• W4225319387 creator A5018753809 @default.
• W4225319387 creator A5019923674 @default.
• W4225319387 creator A5020996390 @default.
• W4225319387 creator A5025688165 @default.
• W4225319387 creator A5029159537 @default.
• W4225319387 creator A5029813171 @default.
• W4225319387 creator A5030601121 @default.
• W4225319387 creator A5037416583 @default.
• W4225319387 creator A5037526878 @default.
• W4225319387 creator A5037878906 @default.
• W4225319387 creator A5041065594 @default.
• W4225319387 creator A5045731423 @default.
• W4225319387 creator A5047911909 @default.
• W4225319387 creator A5049461398 @default.
• W4225319387 creator A5049503939 @default.
• W4225319387 creator A5050723566 @default.
• W4225319387 creator A5050726526 @default.
• W4225319387 creator A5056460836 @default.
• W4225319387 creator A5057927036 @default.
• W4225319387 creator A5065032765 @default.
• W4225319387 creator A5067154165 @default.
• W4225319387 creator A5069449708 @default.
• W4225319387 creator A5069758923 @default.
• W4225319387 creator A5071900105 @default.
• W4225319387 creator A5075349449 @default.
• W4225319387 creator A5076034488 @default.
• W4225319387 creator A5076769955 @default.
• W4225319387 creator A5080184636 @default.
• W4225319387 creator A5080736692 @default.
• W4225319387 creator A5081326206 @default.
• W4225319387 creator A5086620890 @default.
• W4225319387 creator A5090009905 @default.
• W4225319387 creator A5091433944 @default.
• W4225319387 date "2022-05-01" @default.
• W4225319387 modified "2023-09-29" @default.
• W4225319387 title "Reaching beyond maximum grade: progress and future directions for modernising the assessment and reporting of adverse events in haematological malignancies" @default.
• W4225319387 cites W1842042263 @default.
• W4225319387 cites W1976281058 @default.
• W4225319387 cites W2428296383 @default.
• W4225319387 cites W2606815537 @default.
• W4225319387 cites W2620925856 @default.
• W4225319387 cites W2744261860 @default.
• W4225319387 cites W2749791749 @default.
• W4225319387 cites W2763751953 @default.
• W4225319387 cites W2773804840 @default.
• W4225319387 cites W2782908833 @default.
• W4225319387 cites W2787301955 @default.
• W4225319387 cites W2787726379 @default.
• W4225319387 cites W2803946275 @default.
• W4225319387 cites W2808076983 @default.
• W4225319387 cites W2808391935 @default.
• W4225319387 cites W2884699586 @default.
• W4225319387 cites W2897499075 @default.
• W4225319387 cites W2902292458 @default.
• W4225319387 cites W2905567470 @default.
• W4225319387 cites W2905654445 @default.
• W4225319387 cites W2913429766 @default.
• W4225319387 cites W2914157560 @default.
• W4225319387 cites W2914579361 @default.
• W4225319387 cites W2915828920 @default.
• W4225319387 cites W2927325608 @default.
• W4225319387 cites W2975834093 @default.
• W4225319387 cites W2981471534 @default.
• W4225319387 cites W2986446283 @default.
• W4225319387 cites W3003402209 @default.
• W4225319387 cites W3004611567 @default.
• W4225319387 cites W3007702378 @default.
• W4225319387 cites W3024978145 @default.
• W4225319387 cites W3030609157 @default.
• W4225319387 cites W3046970338 @default.
• W4225319387 cites W3047899229 @default.
• W4225319387 cites W3080256401 @default.
• W4225319387 cites W3081993647 @default.
• W4225319387 cites W3096320898 @default.
• W4225319387 cites W3096622856 @default.
• W4225319387 cites W3097870063 @default.
• W4225319387 cites W3107431966 @default.
• W4225319387 cites W3108118108 @default.
• W4225319387 cites W3109491552 @default.
• W4225319387 cites W3110120874 @default.
• W4225319387 cites W3118788544 @default.
• W4225319387 cites W3119523053 @default.
• W4225319387 cites W3120322710 @default.
• W4225319387 cites W3120738879 @default.
• W4225319387 cites W3129887255 @default.
• W4225319387 cites W3131746895 @default.
• W4225319387 cites W3135952809 @default.
• W4225319387 cites W3156345740 @default.
• W4225319387 doi "https://doi.org/10.1016/s2352-3026(22)00045-x" @default.

• next